Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Identification of a novel six autophagy-related genes signature for the prognostic and a miRNA-related autophagy predictor for anti-PD-1 therapy responses in prostate cancer.

Tytuł:
Identification of a novel six autophagy-related genes signature for the prognostic and a miRNA-related autophagy predictor for anti-PD-1 therapy responses in prostate cancer.
Autorzy:
Wu L; Department of Oncology, Zhuhai People's Hospital (Zhuhai Hospital affiliated with Jinan University), Zhuhai, Guangdong Province, P. R. China.
Quan W; Department of Oncology, Zhuhai People's Hospital (Zhuhai Hospital affiliated with Jinan University), Zhuhai, Guangdong Province, P. R. China.
Yue G; Zunyi Medical University, Zunyi, Guizhou Province, P. R. China.
Luo Q; Department of Oncology, Affiliated Zhuhai Hospital, Southern Medical University, Zhuhai, Guangdong Province, P. R. China.
Peng D; Department of Oncology, Zhuhai People's Hospital (Zhuhai Hospital affiliated with Jinan University), Zhuhai, Guangdong Province, P. R. China.
Pan Y; Department of Oncology, Zhuhai People's Hospital (Zhuhai Hospital affiliated with Jinan University), Zhuhai, Guangdong Province, P. R. China. .
Zhang G; Department of Oncology, Zhuhai People's Hospital (Zhuhai Hospital affiliated with Jinan University), Zhuhai, Guangdong Province, P. R. China. .; Zunyi Medical University, Zunyi, Guizhou Province, P. R. China. .
Źródło:
BMC cancer [BMC Cancer] 2021 Jan 05; Vol. 21 (1), pp. 15. Date of Electronic Publication: 2021 Jan 05.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: London : BioMed Central, [2001-
MeSH Terms:
Autophagy*
Antineoplastic Agents, Immunological/*therapeutic use
Biomarkers, Tumor/*genetics
MicroRNAs/*genetics
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Prostatic Neoplasms/*pathology
RNA, Messenger/*metabolism
Gene Expression Regulation, Neoplastic ; Gene Regulatory Networks ; Humans ; Male ; Prognosis ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/genetics ; RNA, Messenger/genetics ; Survival Rate ; Transcriptome
References:
Sci Rep. 2017 Feb 24;7:43378. (PMID: 28233816)
Exp Ther Med. 2019 Apr;17(4):3035-3040. (PMID: 30906477)
J Cancer. 2019 Jan 29;10(4):1023-1031. (PMID: 30854108)
Front Immunol. 2018 May 29;9:1051. (PMID: 29896191)
J Cell Physiol. 2019 Jul;234(7):9927-9942. (PMID: 30536403)
Int J Cancer. 2020 Mar 15;146(6):1686-1699. (PMID: 31381135)
Nat Rev Genet. 2012 Mar 13;13(4):271-82. (PMID: 22411466)
Gastroenterology. 2013 Nov;145(5):1133-1143.e12. (PMID: 23916944)
J Extracell Vesicles. 2017 May 26;6(1):1321455. (PMID: 28717418)
Mod Pathol. 2009 Feb;22(2):261-72. (PMID: 18953328)
J Immunol Res. 2017;2017:1278081. (PMID: 29362722)
Cell Mol Biol (Noisy-le-grand). 2005 Oct 24;Suppl 51:OL785-99. (PMID: 16405855)
Inflamm Bowel Dis. 2015 Dec;21(12):2778-86. (PMID: 26332312)
Dig Dis Sci. 2010 Nov;55(11):3171-80. (PMID: 20165982)
Oncol Lett. 2018 May;15(5):7571-7578. (PMID: 29725462)
PLoS One. 2017 Jul 5;12(7):e0180344. (PMID: 28678839)
Cancer Biol Ther. 2012 Apr;13(6):443-9. (PMID: 22313639)
Oncol Lett. 2018 Jul;16(1):1003-1009. (PMID: 29963176)
Genes Dev. 2016 Sep 1;30(17):1913-30. (PMID: 27664235)
Genes Dev. 2019 Jun 1;33(11-12):610-619. (PMID: 31160394)
Cancer. 2018 Aug;124(16):3307-3318. (PMID: 29671878)
Cancer Res. 2017 Nov 1;77(21):e108-e110. (PMID: 29092952)
Proteomics. 2015 Aug;15(15):2597-601. (PMID: 25921073)
Int J Mol Sci. 2019 Mar 06;20(5):. (PMID: 30845775)
Lancet. 2016 Apr 9;387(10027):1540-1550. (PMID: 26712084)
Cancer Discov. 2015 Oct;5(10):1024-39. (PMID: 26382145)
Asian Pac J Cancer Prev. 2014;15(2):577-83. (PMID: 24568460)
Carcinogenesis. 2012 Nov;33(11):2018-25. (PMID: 22902544)
Oncol Lett. 2019 Feb;17(2):1889-1895. (PMID: 30675252)
Genes Dev. 2007 Jun 1;21(11):1367-81. (PMID: 17510285)
Hepatogastroenterology. 2008 Nov-Dec;55(88):2039-44. (PMID: 19260473)
Biochem Biophys Res Commun. 2016 Mar 25;472(1):194-200. (PMID: 26920049)
CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902)
N Engl J Med. 2004 Apr 29;350(18):1828-37. (PMID: 15115829)
Exp Ther Med. 2019 Nov;18(5):3525-3533. (PMID: 31602229)
Adv Exp Med Biol. 2018;1096:117-133. (PMID: 30324351)
Eur J Pharm Sci. 2019 Jun 15;134:116-137. (PMID: 30981885)
Neoplasia. 2003 Mar-Apr;5(2):99-109. (PMID: 12659682)
Pathol Res Pract. 2020 Feb;216(2):152784. (PMID: 31882179)
N Engl J Med. 2015 Oct 22;373(17):1627-39. (PMID: 26412456)
Cells. 2019 Nov 18;8(11):. (PMID: 31752117)
Cell Syst. 2015 Dec 23;1(6):417-425. (PMID: 26771021)
Cancer Discov. 2012 May;2(5):401-4. (PMID: 22588877)
Mol Ther Nucleic Acids. 2018 Dec 7;13:233-243. (PMID: 30317163)
Mol Med Rep. 2015 Jan;11(1):571-6. (PMID: 25322940)
Biomark Insights. 2018 Feb 06;13:1177271918757480. (PMID: 29449776)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
Medicina (Kaunas). 2020 Feb 24;56(2):. (PMID: 32102477)
Nat Rev Cancer. 2017 Sep;17(9):528-542. (PMID: 28751651)
Cold Spring Harb Symp Quant Biol. 2016;81:73-78. (PMID: 28209717)
Biomed Pharmacother. 2019 Jan;109:2128-2135. (PMID: 30551470)
Mol Cancer. 2020 Jan 22;19(1):12. (PMID: 31969156)
Phytomedicine. 2018 Dec 1;51:139-150. (PMID: 30466611)
Front Pharmacol. 2019 Jun 14;10:673. (PMID: 31258479)
Cell. 1994 Jul 29;78(2):191-201. (PMID: 7913880)
Curr Opin Cell Biol. 2010 Apr;22(2):212-7. (PMID: 20056400)
Oncol Lett. 2019 Jan;17(1):843-848. (PMID: 30655837)
Mol Ther. 2007 Jun;15(6):1042-52. (PMID: 17406342)
Chin J Cancer. 2017 Jun 24;36(1):52. (PMID: 28646911)
Semin Cancer Biol. 2013 Oct;23(5):361-79. (PMID: 23811268)
Front Oncol. 2017 Apr 18;7:65. (PMID: 28459042)
J Urol. 2014 Feb;191(2):510-8. (PMID: 23872029)
Autophagy. 2011 Jul;7(7):760-70. (PMID: 21490427)
BMC Cancer. 2019 Jan 8;19(1):29. (PMID: 30621629)
Exp Cell Res. 2018 Jun 1;367(1):1-6. (PMID: 29574020)
Nat Rev Urol. 2014 Sep;11(9):508-16. (PMID: 25134829)
Genome Biol. 2016 Aug 22;17(1):174. (PMID: 27549193)
Life Sci. 2018 Aug 15;207:451-460. (PMID: 29966607)
Sci Signal. 2013 Apr 02;6(269):pl1. (PMID: 23550210)
J Cancer Res Clin Oncol. 2017 Dec;143(12):2571-2579. (PMID: 28849390)
J Biomed Nanotechnol. 2018 Jan 1;14(1):168-178. (PMID: 29463374)
Crit Rev Eukaryot Gene Expr. 2019;29(2):127-139. (PMID: 31679268)
Science. 2018 Mar 23;359(6382):1350-1355. (PMID: 29567705)
Prostate. 2003 Jul 1;56(2):142-9. (PMID: 12746839)
Autophagy. 2015;11(6):961-2. (PMID: 25998418)
Am J Transl Res. 2018 May 15;10(5):1444-1456. (PMID: 29887958)
Mol Carcinog. 2019 Jul;58(7):1234-1247. (PMID: 30883936)
Eur Rev Med Pharmacol Sci. 2016;20(1):92-100. (PMID: 26813458)
Nat Rev Cancer. 2006 Nov;6(11):857-66. (PMID: 17060945)
Cell Oncol (Dordr). 2015 Jun;38(3):195-204. (PMID: 25860498)
Oncol Rep. 2017 Sep;38(3):1679-1687. (PMID: 28713931)
Mol Cancer. 2013 Aug 02;12:86. (PMID: 23915189)
Clin Cancer Res. 2009 Sep 1;15(17):5308-16. (PMID: 19706824)
Grant Information:
No. Qian Ke He LKZ [2013] 10 Guizhou Science and Technology Department; Qian Ke He LH [2014] 7585 Guizhou Science and Technology Department; none Guizhou Science and Technology Department
Contributed Indexing:
Keywords: Autophagy; PD-1; Prostate cancer; miRNA
Substance Nomenclature:
0 (Antineoplastic Agents, Immunological)
0 (Biomarkers, Tumor)
0 (MicroRNAs)
0 (PDCD1 protein, human)
0 (Programmed Cell Death 1 Receptor)
0 (RNA, Messenger)
Entry Date(s):
Date Created: 20210106 Date Completed: 20210514 Latest Revision: 20210514
Update Code:
20240105
PubMed Central ID:
PMC7786978
DOI:
10.1186/s12885-020-07725-0
PMID:
33402116
Czasopismo naukowe
Background: Autophagy is a highly conserved homeostatic process in the human body that is responsible for the elimination of aggregated proteins and damaged organelles. Several autophagy-related genes (ARGs) contribute to the process of tumorigenesis and metastasis of prostate cancer (PCa). Also, miRNAs have been proven to modulate autophagy by targeting some ARGs. However, their potential role in PCa still remains unclear.
Methods: An univariate Cox proportional regression model was used to identify 17 ARGs associated with the overall survival (OS) of PCa. Then, a multivariate Cox proportional regression model was used to construct a 6 autophagy-related prognostic genes signature. Patients were divided into low-risk group and high-risk group using the median risk score as a cutoff value. High-risk patients had shorter OS than low-risk patients. Furthermore, the signature was validated by ROC curves. Regarding mRNA and miRNA, 12 differentially expressed miRNAs (DEMs) and 1073 differentially expressed genes (DEGs) were detected via the GEO database. We found that miR-205, one of the DEMs, was negatively regulated the expression of ARG (NKX2-3). Based on STRING analysis results, we found that the NKX2-3 was moderately related to the part of genes among the 6 autophagy-related genes prognostic signature. Further, NKX 2-3 was significantly correlated with OS and some clinical parameters of PCa by cBioProtal. By gene set enrichment analysis (GSEA). Lastly, we demonstrated that the association between NKX2-3 and tumor mutation burden (TMB) and PDCD1 (programmed cell death 1) of PCa.
Results: We identified that the six ARGs expression patterns are independent predictors of OS in PCa patients. Furthermore, our results suggest that ARGs and miRNAs are inter-related. MiR-205 was negatively regulated the expression of ARG (NKX2-3). Further analysis demonstrated that NKX2-3 may be a potential biomarker for predicting the efficacy of anti-PD-1 therapy in PCa.
Conclusions: The current study may offer a novel autophagy-related prognostic signature and may identify a promising miRNA-ARG pathway for predicting the efficacy of anti-PD-1 therapy in PCa.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies